Every weekend, I dig into our insider filings tracker looking for the biggest conviction buys — and this week we saw activity across healthcare, aerospace, asset management, internet, insurance, and consumer names.
Target didn't have to be "Great" today. They didn't even have to be good.
Since briefly becoming America's retail comfort food during COVID Target has been on an epic run of failure. The misses have only been interrupted only by short...
Nice comeback run for IBM. That being said, an upper target has appeared and it's one we should take seriously. IF long THEN think of taking some profit or tightening the stop as this level approaches. Don't short until we have a '...
While most of the heavyweights have already reported their quarterly earnings, there are still plenty of names left on the docket. And as always, earnings reports can be a powerful catalyst.
Today's trade is in a $39B leading provider of software solutions for the global life sciences sector that is on the verge of breaking multi-year highs with an eye towards making a run at all-time highs.
I just returned from the annual ISPOR show which showcases companies which tell the 'value' of a therapy coming to market ... thru a combination of "evidence synthesis, economic modeling or RWE (Real World Evidence) studies very smart people are able...
